If you look at the stem cell industry the major problem is that everyone is trying to process on-site. Typically these on-site locations are not laboratories but rather just a side room in a physician's office. With this IRB approval it seems that CRYO can offer their services to physician for studies the right way.
In other words, they just entered a whole new market of providing stem cells to therapeutic locations.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.